Professor Jose G. Montoya, MD, has moved to the next phase in his studies of the antiviral drug valganciclovir (ValcyteTM
) in “Chronic Fatigue Syndrome patients who have elevated antibody titers against Human Herpes Virus 6 (HHV-6) and Epstein-barr Virus and are experiencing long-standing fatigue and cognitive impairment."
The continuing study, which is being conducted at Stanford University in Calfornia’s San Francisco Bay Area, will evaluate whether valganciclovir has a significant and real benefit on the central core of symptoms experienced by these patients. Another objective is to characterize a quantifiable biological marker in these patients that would facilitate the identification of those likely to respond positively to valganciclovir.
To read about the study (ClinicalTrials.gov identifier number NCT00478465), which is ongoing and therefore not recruiting participants, go to http://www.clinicaltrials.gov/ct/show/NCT00478465?order=1